Impact of economic sanctions on access to noncommunicable diseases medicines in the islamic republic of Iran;Impact des sanctions économiques sur l’accès aux médicaments pour le traitement des maladies non transmissibles en République islamique d’Iran

Eastern Mediterranean Health Journal

Volumn 24, Issue 1, 2018, Pages 42-51

  Kheirandish, Mehrnaz ^a,b   Varahrami, Vida ^c   Kebriaeezade, Abbas ^a   Cheraghali, Abdol Majid ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Department of Drug Regulatory Affairs   (Iran)

^c SHAHID BEHESHTI UNIVERSITY   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug access; Drug shortage; Economic crisis; Economic sanctions; Noncommunicable diseases

Indexed keywords

ALPHA2B INTERFERON; BECLOMETASONE; BETA1A INTERFERON; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; BUSERELIN; CAPECITABINE; CLADRIBINE; DAUNORUBICIN; DOCETAXEL; ERLOTINIB; ESTRAMUSTINE PHOSPHATE; FLUDARABINE PHOSPHATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLIBENCLAMIDE; GLICLAZIDE; IMATINIB; INSULIN GLARGINE; INTERFERON BETA SERINE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; RALOXIFENE; REPAGLINIDE; SALBUTAMOL; SALMETEROL; TAMOXIFEN; UNINDEXED DRUG; PRESCRIPTION DRUG;

ARTICLE; ASTHMA; BANK ACCOUNT; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG INDUSTRY; ECONOMIC ASPECT; HUMAN; IRAN; MALIGNANT NEOPLASM; MARKETING; MULTIPLE SCLEROSIS; NON COMMUNICABLE DISEASE; ECONOMICS; HEALTH CARE DELIVERY; NEOPLASM;

ASTHMA; DIABETES MELLITUS; HEALTH SERVICES ACCESSIBILITY; HUMANS; IRAN; MULTIPLE SCLEROSIS; NEOPLASMS; NONCOMMUNICABLE DISEASES; PRESCRIPTION DRUGS;

EID: 85045205374     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2018.24.1.42     Document Type: Article

References (35)

1. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009 Jan 9-240:(9659) 373;17. https://doi.org/10.1016/S6-61762(08)6736-0140 PMID:19042012
2. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2017 Jan 76-403:(10067) 389;28. https://doi.org/10.1016/S9-31599(16)6736-0140 PMID:27832874
3. What is universal coverage? World Health Organization (http://www.who.int/health_financing/universal_coverage_definition/en/, accessed 11 March 2017).
4. Rashidian A, Jahanmehr N, Jabbour S, Zaidi S, Soleimani F, Bigdeli M. Bibliographic review of research publications on access to and use of medicines in low-income and middle-income countries in the Eastern Mediterranean Region: identifying the research gaps. BMJ Open 3:10; 2013 e003332. https://doi.org/10.1136/bmjopen003332-2013-.
5. Kheirandish M, Rashidian A, Bigdeli M. A news media analysis of economic sanction effects on access to medicine in Iran. J Res Pharm Pract. 2015 Oct-Dec;205-199:(4) 4. https://doi.org/042-2279/10.4103X.167042 PMID:26645026
6. Yaghoubifard S, Rashidian A, Kebriaeezadeh A, Majdzadeh R, Hosseini SA, Akbari Sari A, et al. (Developing a conceptual framework and a tool for measuring access to, and use of, medicines at household level) (HH-ATM tool). Public Health. 2015 May;52-444:(5) 129. https://doi.org/10.1016/j.puhe.2015.01.026 PMID:25769347
7. Kheirandish M, Rashidian A, Kebriaeezade A, Cheraghali AM, Soleymani F. A review of pharmaceutical policies in response to economic crises and sanctions. J Res Pharm Pract. 2015 Jul-Sep;22-115:(3) 4. https://doi.org/042-2279/10.4103X.162361 PMID:26312250
8. Lewis M, Verhoeven M. Financial crises and social spending: the impact of the 2009-2008 crisis. Washington: World Bank; 2010.
9. Petrescu IM. The Humanitarian impact of economic sanctions. Job Market Paper. 2007.
10. Garfield R. The impact of economic sanctions on health and well-being. Overseas Development Institute; 1999.
11. Gibbons E, Garfield R. The impact of economic sanctions on health and human rights in Haiti, 1994-1991. Am J Public Health. 1999 Oct;504-1499:(10) 89. https://doi.org/10.2105/AJPH.89.10.1499 PMID:10511830
12. Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev. 2011 Dec;79-69:(2) 4. https://doi.org/10.5655/smr.v4i2.1004 PMID:23093885
13. Garfield R, Devin J, Fausey J. The health impact of economic sanctions. Bull N Y Acad Med. 1995 Winter;69-454:(2) 72. PMID:10101382
14. Access to medicines. Statement: 13 March 2009. World Health Organization (http://apps.who.int/medicinedocs/en/d/Js2296e/1.html, accessed 28 February 2018).
15. Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 2010-1997; policy implications for developing countries. Daru. 52:(1) 21;28 06 2013. https://doi.org/52-21-2231-2008/10.1186 PMID:23805853
16. Cheraghali AM. Impacts of international sanctions on Iranian pharmaceutical market. Daru. 2013 Jul 64:(1) 21;31. https://doi.org/-2231-2008/10.118664-21 PMID:23902642
17. The impact of sanctions on Iranian people healthcare. Institut International pour la Paix, la Justice et les Droits de l’Homme. 2013.
18. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low-and middle-income countries. Bull World Health Organ. 2007 Apr;88-279:(4) 85. https://doi.org/10.2471/BLT.06.033647 PMID:17546309
19. Ghiasi G, Rashidian A, Kebriaee A, Dorkoosh FA, Salamzadeh J. Access to Asthma Medicines in Tehran; Iran. Value Health. 2014 Nov;7(17): A781. https://doi.org/10.1016/j.jval.2014.08.375 PMID:27202896
20. Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J. 2009 May-Jun;9-591:(3) 15. PMID:19731775
21. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010 Mar;6-143:(2) 13. PMID:20187669
22. WHO country cooperation strategy at a glance: Islamic Republic of Iran. World Health Organization; 2017) http://apps.who.int/iris/bitstream/10665/136898/1/ccsbrief_irn_en.pdf, (accessed 21 February 2018).
23. Guidelines for ATC classification and DDD assignment 2013. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; (2012) https://www.whocc.no/filearchive/publications/2013_1guidelines.pdf, accessed 21 February 2018).
24. DDD alterations from 2018-2005. (Oslo: WHO Collaborating Centre for Drug Statistics Methodology) https://www.whocc.no/atc_ddd_alterations__cumulative/ddd_alterations/, (accessed 28 February 2018).
25. Sarayani A, Rashidian A, Gholami K. Low utilisation of diabetes medicines in Iran, despite their affordability) (2012-2000): a time-series and benchmarking study. BMJ Open. 10(4;16 10 2014):e005859. https://doi.org/10.1136/bmjopen005859-2014 PMID:25324322
26. List of DDDs combined products. Oslo: WHO Collaborating Centre for Drug Statistics Methodology) http://www.whocc.no/ddd/list_of_ddds_combined_products/, (accessed 21 February 2018).
27. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002 Aug;309-299:(4) 27. https://doi.org/10.1046/j.2710.2002.00430-1365.x PMID:12174032
28. Webel K. Greene, WH. Econometric analysis. Statistische Hefte. 4-983:(4) 52;2011.
29. Bessler M, Garfield R, McHugh G. Sanctions assessment handbook. United Nations and the Inter-Agency Standing Committee; 2004.
30. Van der Stuyft P, De Vos P, Hilderbrand K. USA and shortage of food and medicine in Cuba. Lancet. 1997 Feb 363:(9048) 349;1. https://doi. org/10.1016/S3-62872(05)6736-0140 PMID:9024412
31. Garfield R. USA and shortage of food and medicine in Cuba. Lancet. 1997 Feb 363:(9048) 349;1. https://doi.org/10.1016/S1-62871(05)6736-0140 PMID:9024411
32. Shariatirad S, Maarefvand M. Sanctions against Iran and the impact on drug use and addiction treatment. Int J Drug Policy. 2013 Nov;-636:(6) 24 7. https://doi.org/10.1016/j.drugpo.2013.04.003 PMID:23683411
33. Karimi M, Haghpanah S. The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran. Health Policy. 2015 Feb;43-239:(2) 119. https://doi.org/10.1016/j.healthpol.2014.12.011 PMID:25564279
34. Gorji A. Sanctions against Iran: the impact on health services. Iran J Public Health. 2014 Mar;2-381:(3) 43. PMID:25988101
35. Namazi S. Sanctions and medical supply shortages in Iran. Wilson Center; 2013) http://www.wilsoncenter.org/publication/sanctions-andmedical-supply-shortages-iran, (accessed 21 February 2018).